An interventional study of Black Breast Cancer Survivor's Intervention in Breast Cancer, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Breast Neoplasms by M.D. Anderson Cancer Center — 29 open to participants now, 71 under way, 3 of them phase 3. Breast Neoplasms · M.D. Anderson Cancer Center.
Among the 230 studies in Breast Neoplasms by M.D. Anderson Cancer Center, this one is the 71st largest by planned enrollment of the 177 interventional ones that give a count, is one of 8 that started in 2025, is one of 61 with no phase, reaches primary completion later than 31 of the 70 other live ones, and was the 217th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →29 of the 230 studies in Breast Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 69 · Phase 3 15 · Phase 4 1
First in 1995; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 56 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 40 across the 177 interventional studies, 60 across the 53 observational. Of the 134 that completed or were terminated, 50 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
31 of the studies in Breast Neoplasms by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02276443M.D. Anderson Cancer CenterMolecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | 2026-11-30 |
| NCT05675579M.D. Anderson Cancer CenterA Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) | 2026-12-31 |
| NCT00877500M.D. Anderson Cancer CenterIxabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | 2026-12-31 |
| NCT02754752M.D. Anderson Cancer CenterElectroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment | 2026-12-31 |
| NCT02455791M.D. Anderson Cancer CenterFeasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery | 2026-12-31 |
Add all 31 to your calendar (.ics) → With an account.
Among the 230 studies in Breast Neoplasms by M.D. Anderson Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this research study is to learn about the effects of the BBCSI course on the quality of life of Black breast cancer survivors.
A community-based and peer-led Black Breast Cancer Survivor's Intervention (BBCSI) course has been developed to help improve the quality of life of Black breast cancer survivors.
Primary Objectives:
Develop a prototype of the BBCSI curriculum and assess satisfaction of the intervention.
Determine the preliminary efficacy of the BBCSI.
Evaluate fidelity, feasibility, acceptability, barriers, and facilitators of the BBCSI.
Inclusion Criteria:
Master Trainers:
To be eligible to participate in this study, an individual must meet all the following criteria:
Participants:
To be eligible to participate in this study, an individual must meet all the following criteria:
Community Interventionists:
To be eligible to participate in this study, an individual must meet all the following criteria:
General Exclusion Criteria:
Additional Exclusion Criteria - Community Interventionists
1. Has not previously participated in and completed the study intervention as a participant
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be recruited through our Community Based Organizations (CBOs) and other community collaborator networks.
Behavioral: Black Breast Cancer Survivor's Intervention
Participants will be recruited through our Community Based Organizations (CBOs) and other community collaborator networks.
Behavioral: Black Breast Cancer Survivor's Intervention
Participants will complete the BBCSI course (1-hour virtual sessions every week for 6 weeks), answer questionnaires before and after the course, and provide urine samples.
Safety and Adverse Events (AEs)
Safety and Adverse Events (AEs)
Time frame: Time Frame: Through study completion; an average of 1 year
Started Aug 2025 (actual). Primary completion is estimated for Aug 2027, 24 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 24 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.